Overview

CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2035-09-01

Target enrollment:

Participant gender:

Summary

The investigators designed a phase III clinical trial involving hormone receptor-positive and HER2-positive stage I breast cancer patients. This trial aims to evaluate the efficacy and safety of a treatment regimen combining CDK4/6 inhibitors, endocrine therapy, and anti-HER2 therapy compared with the traditional approach of chemotherapy combined with anti-HER2 therapy.

Phase:

PHASE3

Details

Lead Sponsor:

Fudan University

Treatments:

Standard of Care